• Clinical and Experimental Reproductive Medicine
• /
• 제39권1호
• /
• pp.22-27
• /
• 2012

Objective: To evaluate the effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase (MDP-EL) in comparison with standard GnRH agonist luteal long protocol (LP) in each non-obese and obese polycystic ovary syndrome (PCOS) women undergoing IVF. Methods: Two hundred eleven infertile women with PCOS were recruited and randomized to undergo either GnRH antagonist MDP-EL (antagonist group) or standard GnRH agonist luteal LP (agonist group). IVF cycle outcomes were compared between the two groups. Results: Total dose and days of recombinant human follicle stimulating hormone (rhFSH) administered were significantly fewer in the antagonist group than in the agonist group. Incidence of severe ovarian hyperstimulation syndrome was significantly lower in the antagonist group. However, IVF and pregnancy outcomes were similar in the two groups. When all subjects were divided into non-obese and obese subgroups, in non-obese PCOS subgroup, IVF and pregnancy outcomes were comparable in the antagonist and agonist groups but total dose and days of rhFSH were also significantly fewer in the antagonist group. Similar findings were also observed in obese PCOS subgroup. Conclusion: GnRH antagonist MDP-EL is at least as effective as GnRH agonist LP and may be a more patient-friendly alternative in controlled ovarian stimulation for PCOS patients undergoing IVF, independent of body mass index.

• Clinical and Experimental Reproductive Medicine
• /
• 제38권4호
• /
• pp.228-233
• /
• 2011

Objective: To investigate the effectiveness of GnRH antagonist multiple-dose protocol (MDP) with oral contraceptive pill (OCP) pretreatment in poor responders undergoing IVF/ICSI, compared with GnRH antagonist MDP without OCP pretreatment and GnRH agonist low-dose long protocol (LP). Methods: A total of 120 poor responders were randomized into three groups according to controlled ovarian stimulation (COS) options; GnRH antagonist MDP after OCP pretreatment (group 1), GnRH antagonist MDP without OCP pretreatment (group 2) or GnRH agonist luteal low-dose LP without OCP pretreatment (group 3). Patients allocated in group 1 were pretreated with OCP for 21days in the cycle preceding COS, and ovarian stimulation using recombinant human FSH (rhFSH) was started 5 days after discontinuation of OCP. Results: There were no differences in patients' characteristics among three groups. Total dose and days of rhFSH used for COS were significantly higher in group 3 than in group 1 or 2. The numbers of mature oocytes, fertilized oocytes and grade I, II embryos were significantly lower in group 2 than in group 1 or 3. There were no significant differences in the clinical pregnancy rate and implantation rate among three groups. Conclusion: GnRH antagonist MDP with OCP pretreatment is at least as effective as GnRH agonist low-dose LP in poor responders and can benefit the poor responders by reducing the amount and duration of FSH required for follicular maturation.

• 한국수정란이식학회:학술대회논문집
• /
• 한국수정란이식학회 2002년도 국제심포지엄
• /
• pp.97-97
• /
• 2002

Human eryhropoietin (EPO) is acidic glycoprotein hormone that plays key role in hematopoiesis by facilitating differentiation of erythrocyte and formation of hemoglobin (Hb) and is used for the treatment of anemia. Human EPO is consist of 166 amino acids which is modified by three N-glycosylations (24, 38, 83) and single O-glycosylation (126). N-glycosylation is reported to be related to the cellular secretion and activity of EPO. In this study, we examined effects of mutagenesis in glycosylation site of recombinat hEPO for the cellular secretion during production from cultured CHO cell. We produced rhEpo which was cloned by PCR from human liver cDNA (TaKaRa) in cultured CHO cell. Using supernatant of the culture, ELISA assay and western analysis were performed. To estimate biological activity, 20IU of rhuEpo was subcutaneously injected into four ICR mice. After 8 days, HCT level was increased average 13 per cent, RBC was increased ca. 2${\times}$10$\^$6//${\mu}\ell$. In disease model Rat (anemia c-kit, WSRC-WS/WS), HCT was increased ca. 12%, RBC was increased ca. 1.6${\times}$10$\^$6//${\mu}\ell$. These results suggests that rhEpo we produced has biological activity. To remove glycosylation site by substituting 24, 38, 83, and 126th asparagine (or serine) with glutamic acid, overlapping -extension site-directed mutagenesis was performed. To add novel glycosylation sites, 69, 105th leucine was mutated to asparagine. Mutant EPO construct was transfected into CHO cell. Supernatant of the cell culture was analyzed using ELISA assay with monoclonal anti-EPO antibody (Medac, Germany). Since, several reports for mutagenesis of glycosylation sites showed case-by-case results, we examined both transient expression and stable expression. Addition of novel glycosylation sites resulted no secretion while deletion mutants had little effect except some double deletion mutants (24/83 and 38/83) and triple mutant. We suggest that not single but combination of glycosyl group affect secretion of EPO.

• 한국가축번식학회지
• /
• 제26권2호
• /
• pp.95-104
• /
• 2002

본 연구는 사람의 조혈촉진 유전자(hEPO)가 도입된 형질전환 돼지를 생산하기 위해 사계절동안 수행하였다. 약 8∼15개월령의 순종의 랜드레이스 경산돈 및 미경산돈 42두는 유전자 미세주입을 위한 1세포기 단계의 수정란 채란 및 이식을 위해 사용하였으며, 발정동기화 및 과배란 방법은 PG 600 주입 후 9일간 매일 20mg의 altrenogest를 사료에 첨가하여 급여하였다. Altrenogest를 9일간 급여 후 1,500IU의 PMSG와 500IU의 hCG를 주입하므로서 과배란을 유도하였다. 미세주입을 위한 유전자는 mouse whey acidic protein(mWAP) 프로모터에 hEPO 유전자를 연결하여 준비하였으며, 호르몬 처리후 23두의 공란돈으로 부터 650개의 난자를 회수하였으며, 이 중 83.1%(540/650)는 DNA 미세주입을 위해 전핵을 관찰할 수 있는 1-세포기의 수정란이었다. 이중 유전자가 미세주입 된 543개의 난자를 19두의 수란돈에 이식하였으며 7두의 임신돈으로부터 47두의 자돈을 생산하였다. 생산된 자돈 47두로부터 꼬리조직으로부터 분리된 DNA의 PCR 검정 결과 수컷 1두가 형질전환 양성반응을 나타내어 2.13%의 형질전환율을 나타내었으며, 이러한 연구의 결과는 생체반응기(bioreactor)연구에 있어서 형질전환 돼지생산의 성공적이며 유용한 정보를 제공할 것으로 사료된다.

• Nutrition Research and Practice
• /
• 제17권2호
• /
• pp.228-240
• /
• 2023

BACKGROUND/OBJECTIVES: Cocoa consumption is associated with health benefits due to its high content of polyphenols. However, the effects of short-term cocoa consumption remain unclear. We aimed to determine the effects generated by cocoa consumption (for 7 days) in young adults in normoweight and class II obesity. SUBJECTS/METHODS: Before-and-after study was carried out in normoweight (NW) (n = 15) and class II obesity (CIIO) (n = 15) young adults. The NW and CIIO participants consumed 25 and 39 g of cocoa, respectively, per day for 7 days. The effect of cocoa consumption was evaluated on the lipid profile, insulin resistance (IR), and inflammation. Oxidative damage was also examined by assessing the biomarkers of oxidative damage in plasma. In addition, recombinant human insulin was incubated with blood obtained from the participants, and the molecular damage to the hormone was analyzed. RESULTS: Cocoa consumption resulted in decreased low-density lipoprotein-cholesterol in both groups (P = 0.04), while the total cholesterol, high-density lipoprotein cholesterol, and triglycerides were maintained at the recommended levels. Initially, IR was detected in the CIIO group (homeostasis model assessment [HOMA] = 4.78 ± 0.4), which is associated with molecular damage to insulin. Interestingly, intervention with cocoa resulted in improved IR (HOMA = 3.14 ± 0.31) (P = 0.0018) as well as molecular damage to insulin. Finally, cocoa consumption significant decreased the arginase activity (P = 0.0249) in the CIIO group; this is a critical enzymatic activity in the inflammatory process associated with obesity. CONCLUSIONS: The short-term consumption of cocoa improves the lipid profile, exerts anti-inflammatory effects, and protects against oxidative damage. Results of this study indicate that cocoa consumption can potentially improve IR and restore a healthy redox status.

• 한국가축번식학회지
• /
• 제23권3호
• /
• pp.205-212
• /
• 1999

본 연구는 rBST, Vit. E 및 Se의 투여가 한우 종모우의 혈청내 Se과 vitamin E의 농도 변화에 미치는 영양을 검토하였다. 1. rBST, Vit. E 및 Se 투여가 한우 종모우의 혈청 내 Se농도 변화에 미치는 영향을 조사한 결과, 혈청내 Se 농도는 Vit. E와 Se 혼합투여구가74.09ppb/ml로서 대조구(64.55ppb/ml)와 rBST투여구(65.50ppb/ml) 및 vit. E 투여구(68.15ppb/m1)보다 높은 농도를 나타냈으나(P<0.05), selenium 투여구(73.11ppb/ml)와는 통계적 유의차가 없었다(P>0.05). 2. rBST, Vit. E 및 Se 투여가 한우 종모우의 혈청 내 Vit. E 농도 변화에 미치는 영향을 조사한 결과, 혈청내 Vit. E농도는 Vit. E투여구와 혼합투여구가 각각 2.80 및 2.75ppm/ml로서 여타구(대조구, 2.27 ; rBST투여구, 2.32 및 Se투여구, 2.58ppm/rnl)보다 다소 높게 나타났지만 통계적 유의차는 인정되지 않았다(P>0.05). 3. Vt. E 투여구, Se 투여구 및 혼합투여구에서 투여 횟수에 따른 혈청내 Se과 Vit. E의 농도 변화는 모든 투여구에서 투여 횟수가 증가함에 따라 혈청내 농도가 증가하였다.

• 한국가축번식학회지
• /
• 제23권3호
• /
• pp.191-203
• /
• 1999

본 연구는 rBST, Vito E 및 Se 투여가 한우 종모우의 정액성상에 미치는 효과를 검토하였고 정액의 동결보존 시 정액희석액에 taurine의 첨가가 융해 후 정액성상에 미치는 영향을 검토하였다. 1. rBST, Vit. E, Se 및 Vit. E와 Se 혼합 투여가 한우 종모우의 정액량, 정자농도 및 수소이온농도 (pH)에 미치는 영향을 조사한 결과, 정액량과 수소이온농도는 처리구간에 커다란 차이가 없었으며(P＜0.05), 정자의 평균농도는 각각 13.50$\pm$2.32, 16.26$\pm$2.65, 17.07$\pm$2.61, 19.23$\pm$2.07 및 19.46$\pm$2.06$\times$$10^{8}$ 정자/$m\ell$로서 Se 투여구와 혼합투여구가 대조구, rBST 투여구 및 Vit. E 투여구보다 통계적으로 유의하게 높은 정자농도를 나타냈다 (P＜0.05). 2. rBST. Vit. E 및 Se 투여가 한우 종모우의 정액의 동결융해시 정액성상에 미치는 영향을 조사한 결과, 정자의 운동율과 기형율은 투여구간에 통계적 유의차는 없었으나, 정자의 생존율은 혼합투여구가 48.24%로서 대조구 (44.48%)보다 통계적으로 유의하게 높은 생존율을 나타냈으며 (P＜0.05), rBST 투여구, Vit. E 투여구 및 Se 투여구는 각각 46.48%, 47.28% 및 46.34%로서 대조구와 통계적 유의차는 인정되지 않았다. 3. 정액의 동결보존시 정액회석액에 taurine의 첨가가 정액의 융해 후 정액성상에 미치는 영향을 조사한 결과는 총정자수, 운동율, 생존율 및 기형율에서 taurine 첨가구가 taurine 무첨가구보다 다소 좋은 결과를 얻었지만 커다란 차이가 없었다. 4. rBST, Vit. E 및 Se 투여가 정자의 수정능획득과 첨체반응에 미치는 효과를 조사한 결과, 수정능 획득과 침체반응이 모두 일어나지 않는 비율(F율)과 모두 일어난 비율 (AR율) 은 투여구간에 커다란 차이가 없었다 (P＜0.05). 5. 정액의 동결보존 시 taurine 의 첨가가 융해후 정자의 수정능획득과 첨체반응에 미치는 영향을 조사한 결과는 수정능 획득이 일어났지만 첨체 반응이 일어나지 않은 비율 (B율)과 AR 율에서는 투여구간에 커다란 차이가 없었지만, F율은 taurine 첨가구가 taurine 무첨가구보다 낮은 비율을 나타났다 (P＜0.05).